Coiro V, Volpi R, Capretti L, Speroni G, Pilla S, Cataldo S, Bianconcini M, Bazzani E, Chiodera P
Department of Internal Medicine and Biomedical Sciences, University of Parma, Italy.
J Investig Med. 2001 Jul;49(4):330-4. doi: 10.2310/6650.2001.33898.
The presence of an abnormally high thyroid-stimulating hormone (TSH) response to thyrotropin-releasing hormone (TRH) makes it difficult to distinguish some euthyroid obese subjects from subelinically hypothyroid obese patients. Here, we examine whether such distinction may be achieved after treatment with glucocorticoids, which inhibit TSH secretion at the hypothalamic-pituitary level.
TRH tests (200 microg as an intravenous bolus injection) were performed in 30 age- and weight-matched, obese, but otherwise healthy, men. All subjects were tested again with TRH after treatment with dexamethasone (dex) (2 mg/d in four divided doses orally for 3 days).
In all subjects, total thyroxine and triiodothyronine concentrations were in the normal range. According to basal and TRH-stimulated serum thyrotropin (TSH) levels, subjects were divided into the following three groups: group I (n=10), euthyroid subjects; group II (n=10), euthyroid subjects with normal basal but abnormally elevated TSH responses to TRH; group III (n=10), subjects with elevated basal and TRH-induced TSH levels (subclinical hypothyroidism). Basal TSH levels were 1.8+/-0.4 mU/L in group I, 1.7+/-0.3 in group II, and 6.0+/-0.7 in group III. In both groups II and III, TRH-induced TSH increments were above the normal range (maximal increment> 15 mU/L) and were significantly higher than in group I. After the second treatment with TRH, pretreatment with dex significantly decreased both basal TSH levels and peak TSH responses to TRH in all groups. However, a striking percentage decrease (>50%) in TRH-induced peak TSH responses was observed in euthyroid obese subjects of groups I and II, whereas hypothyroid subjects of group III showed only a slight decrement (<25%).
The sensitivity of the TSH secretory system to glucocorticoid inhibitory action is preserved in obese subjects with abnormally elevated TSH response to TRH, but not in subclinically hypothyroid obese patients. The TRH plus dex test might be useful in future studies to understand the mechanisms underlying alterations in TSH secretion in obesity.
促甲状腺激素(TSH)对促甲状腺激素释放激素(TRH)的反应异常升高,使得难以区分一些甲状腺功能正常的肥胖受试者与亚临床甲状腺功能减退的肥胖患者。在此,我们研究在使用糖皮质激素治疗后是否可以实现这种区分,糖皮质激素可在下丘脑 - 垂体水平抑制TSH分泌。
对30名年龄和体重匹配、肥胖但其他方面健康的男性进行TRH试验(静脉推注200微克)。所有受试者在接受地塞米松(dex)治疗(2毫克/天,分4次口服,共3天)后再次进行TRH试验。
所有受试者的总甲状腺素和三碘甲状腺原氨酸浓度均在正常范围内。根据基础和TRH刺激后的血清促甲状腺激素(TSH)水平,受试者分为以下三组:第一组(n = 10),甲状腺功能正常的受试者;第二组(n = 10),基础甲状腺功能正常但对TRH的TSH反应异常升高的甲状腺功能正常的受试者;第三组(n = 10),基础和TRH诱导的TSH水平升高的受试者(亚临床甲状腺功能减退)。第一组的基础TSH水平为1.8±0.4 mU/L,第二组为1.7±0.3,第三组为6.0±0.7。在第二组和第三组中,TRH诱导的TSH增量均高于正常范围(最大增量>15 mU/L),且显著高于第一组。在第二次TRH治疗后,dex预处理显著降低了所有组的基础TSH水平和TRH刺激后的TSH峰值反应。然而,在第一组和第二组的甲状腺功能正常的肥胖受试者中,观察到TRH诱导的TSH峰值反应有显著的百分比下降(>50%),而第三组的甲状腺功能减退受试者仅显示轻微下降(<25%)。
TSH分泌系统对糖皮质激素抑制作用的敏感性在对TRH反应异常升高的肥胖受试者中得以保留,但在亚临床甲状腺功能减退的肥胖患者中则不然。TRH加dex试验可能对未来研究了解肥胖中TSH分泌改变的潜在机制有用。